PrecivityAD2 is a blood test that can now be used alongside a full clinical workup to help identify Alzheimer's-related brain changes in symptomatic adults as young as 40. The FDA cleared it on August 20, 2026, specifically lowering the age floor that had kept blood testing out of reach for most younger-onset families, since C2N Diagnostics' announcement describes it as the first Alzheimer's blood test cleared for that age group. For a family facing memory or thinking changes in a parent, sibling, or spouse in their 40s or 50s, this matters because it opens a faster, less invasive path toward an answer. The questions below are ones a clinician can actually answer at the appointment, based on what the test does, what its results mean, and where it still needs backup from other tools.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does a PrecivityAD2 result actually measure?
- How reliable is a positive or negative result?
- Why does age change the picture for younger-onset families?
- What should happen after the result comes back?
- Does insurance cover it, and does that affect timing?
- Frequently Asked Questions
What does a PrecivityAD2 result actually measure?
PrecivityAD2 uses high-resolution mass spectrometry to measure two blood markers — amyloid beta 42/40 and p-tau217/np-tau217 — and combines them into a single number called the Amyloid Probability Score 2, which runs from 0 to 100, according to Practical Neurology reporting via Healio. The score is reported back as positive, negative, or an intermediate category called "likely positive." That middle category is not rare. In the validation data C2N submitted to the FDA, 17.3% of participants landed in the "likely positive" band, the same Healio report notes.
A family should ask directly which of the three categories their relative's result fell into, because a "likely positive" calls for a different conversation than a clean positive or negative. The test is cleared only as an adjunct to standard clinical evaluation in adults 40 and older who already have cognitive symptoms, according to NeurologyLive's coverage of the clearance. It is not approved for screening someone with no symptoms, and it is not meant to stand alone as a diagnosis.
How reliable is a positive or negative result?
In C2N's FDA validation study of 1,142 participants, a positive result carried a 97.6% positive predictive value for amyloid pathology, and a negative result carried a 93.1% negative predictive value, per the same Healio article. Those numbers describe how often a clear result matches what brain imaging or spinal fluid testing would show — they do not describe the "likely positive" band, which is why that category needs its own conversation with the clinician. A separate real-world study gives a sense of how much the test changes a doctor's confidence.
In a Swedish study presented at AAIC 2026, led by Sebastian Palmqvist's group at Lund University and covering 383 primary-care and 927 secondary-care patients, primary care physicians' diagnostic accuracy rose from 65% before seeing the blood test result to 93% after, and the result changed management in 55.9% of cases, according to Healio's July 2026 report. That cohort was mostly older adults, not a younger-onset sample, so a family can ask how closely their own situation matches the population the test has actually been studied in. Families can bring these specific questions to the appointment:.
- What exact score came back, and which of the three categories does it fall into?
- Is this result being read together with cognitive testing and brain imaging, or on its own?
- If the result is "likely positive," what is the next confirmatory step?
- If the result conflicts with what the imaging or cognitive exam shows, which result carries more weight and why?
Why does age change the picture for younger-onset families?
Younger-onset Alzheimer's refers to symptoms that begin before age 65, and it comes with a wider set of possible explanations than late-onset decline does. A UK memory-clinic study of 429 patients enrolled between 2018 and 2024 found that 81.4% had onset before age 65, and that functional cognitive disorder — a condition affecting thinking that is not caused by underlying brain disease — accounted for 22.3% of that early-onset group, far more common than the 5.0% seen in late-onset patients, per the cohort study published on PMC. Psychiatric conditions were also more common in the younger group.
That matters because a positive amyloid result does not rule out that something else, such as a mood disorder or a functional condition, is also contributing to the symptoms, or is the primary driver. A family can ask the clinician directly what else was considered in the differential diagnosis before or alongside the blood test, and whether a positive amyloid result changes that list or sits alongside it. Joanne Pike, President and CEO of the Alzheimer's Association, said the expanded clearance to age 40 "recognizes that younger-onset Alzheimer's is a reality for many families" and may help them reach a diagnosis and start care planning sooner, according to the Alzheimer's Association's statement. Reaching that diagnosis faster is the benefit; ruling out the wider differential first is the caution that comes with testing a younger population.
What should happen after the result comes back?
Because PrecivityAD2 is adjunctive and produces a score with a built-in gray zone, clinicians recommend asking what specific score was obtained, whether it was interpreted alongside cognitive testing and imaging, and what confirmatory step follows an indeterminate or clinically discordant result, per NeurologyLive. A family walking out of the appointment with just "positive" or "negative" and no further plan has not gotten the full picture the test is designed to support. Questions worth asking before leaving the appointment:.
- What would change about the care plan if this result is confirmed by imaging or spinal fluid testing?
- Does a positive result at this age open access to specific treatments or clinical trials?
- How often should the test or related monitoring be repeated, if at all?
- Who coordinates the next steps — the primary care clinician, a neurologist, or a memory specialist?
Does insurance cover it, and does that affect timing?
Anthem Blue Cross and Blue Shield began covering PrecivityAD2 for eligible members on October 1, 2026, which C2N states makes it the first U.S. insurer to cover the test under a formal medical policy, according to the Las Vegas Sun's report on C2N's announcement.
A family can ask their clinician's office or their own insurer directly whether their plan has a comparable policy, since coverage outside Anthem is not yet established as standard. If coverage isn't yet in place, that's worth knowing before the test is ordered rather than after, since it affects both cost and how quickly a family can move toward a confirmed diagnosis and a care plan.
Frequently Asked Questions
Can PrecivityAD2 be used if someone has no memory symptoms yet, just a family history of Alzheimer's?
No. The FDA clearance covers only adults 40 and older who already have cognitive symptoms; it is not cleared for screening people without symptoms, per NeurologyLive.
Does a positive PrecivityAD2 result mean the person definitely has Alzheimer's?
It means amyloid pathology is highly likely, with a 97.6% positive predictive value in C2N's validation study, but the clearance requires it be used alongside, not instead of, a full clinical evaluation, per Healio.
You Might Also Like
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Questions Younger-Onset Alzheimer’s Families Can Bring to a Clinician
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: What Younger-Onset Alzheimer’s Families Should Know About the News
- The $781 Billion Dementia Economic Estimate in the 2026 NIA Report: Questions Spouses and Partners Can Ask Local Care Programs
